Digene Corp. Receives FDA Clearance for Hybrid Capture CMV DNA Test

Strategic Insights -

Digene Corp., a leading diagnostics company, has received marketing clearance from the U.S. Food and Drug Administration (FDA) for its innovative Hybrid Capture CMV DNA Test. This breakthrough test is designed to rapidly and accurately diagnose CMV (Cytomegalovirus) infection in patients undergoing solid organ transplants, bone marrow transplants, and those with HIV/AIDS. The test boasts exceptional sensitivity, detecting 99% of CMV infections, far outperforming the current culture method's 46% sensitivity.

Key Takeaways:

  • The Digene CMV Test has received marketing clearance from the FDA, marking a significant milestone for the company.
  • The test is intended for diagnosing CMV infection in high-risk patients, including solid organ transplant recipients, bone marrow transplant patients, and those with HIV/AIDS.
  • The test's sensitivity is 99%, compared to the current culture method's 46%, providing clinicians with a more accurate and timely diagnosis.
  • CMV is a common opportunistic infection, with approximately 60% of transplant patients and 95% of HIV/AIDS patients contracting the virus.
  • CMV can lead to complications in various body sites, including the retina, digestive tract, lungs, liver, and central nervous system.
  • An estimated $1 billion is spent annually in the United States on preventing and treating CMV-related diseases.
  • The Digene CMV Test offers an objective result available the same day, as opposed to the current tests that can take up to a month to produce results.
  • The test is designed to help physicians tailor antiviral therapies more effectively, recognizing resistance and projecting disease progression.
  • Evan Jones, Digene Corp., comments on the FDA approval, highlighting the test's potential to significantly improve patient management by providing early disease detection and ensuring that CMV therapies are administered only when necessary.

Sources:

  • [U.S. Food and Drug Administration (FDA)], no date provided.
  • [Digene Corp.], no date provided.
  • [Evan Jones, Digene Corp.], no date provided.